ESR1 and breast cancer: The risks of breast cancer-specific mortality were elevated among women with ER+/PR-, ER-/PR+, and ER-/PR- tumors relative to women with ER+/PR+ tumors across all subcategories of age at cancer diagnosis (Table 2).